Partial
Partially Aligned
Patient Risk:
Medium
Summary
Many core indication/mechanism statements for PROTONIX are supported by the provided label excerpts, but several safety adverse-effect and general interchangeability/clinical-efficacy/general-comparison claims are not supported by the supplied labeling text. Several dosing/administration and eligibility details are only partially supported (e.g., GERD vs erosive esophagitis specificity; pediatric indication age range; formulation splitting/crushing not fully reflected).
Category Scores
Accurate Statements
Protonix is a brand name for pantoprazole.
Drug identity/active ingredient is consistent with label excerpts: PROTONIX (pantoprazole sodium).
Protonix belongs to the class of drugs known as proton pump inhibitors (PPIs).
12.1 Mechanism of Action: “Pantoprazole is a proton pump inhibitor…”.
Protonix reduces the amount of acid produced in the stomach.
12.1 Mechanism: suppresses final step in gastric acid production.
Protonix irreversibly blocks the H+/K+ ATPase enzyme system (the proton pump) in gastric parietal cells.
12.1 Mechanism and general suppression of final step in acid production (consistent with “proton pump inhibitor”).
By irreversibly blocking the proton pump, Protonix decreases acid secretion.
12.1 Mechanism of Action: suppresses final step in gastric acid production.
Protonix is prescribed for gastroesophageal reflux disease (GERD).
1.1 indicates EE associated with GERD; 1.2 maintenance in adult GERD with EE.
Protonix helps heal and relieve symptoms of heartburn and acid regurgitation associated with GERD.
1.1: healing and symptomatic relief of erosive esophagitis; 1.2: reduction in relapse rates of daytime and nighttime heartburn symptoms.
Protonix is used for erosive esophagitis.
1.1: short-term treatment… healing and symptomatic relief of erosive esophagitis.
Protonix aids in healing damage to the esophagus caused by stomach acid.
1.1: healing of erosive esophagitis.
Protonix is used for Zollinger-Ellison syndrome.
1.3: pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Protonix is used for peptic ulcers in combination with antibiotics to eradicate Helicobacter pylori (H. pylori).
No provided label excerpt in the supplied text supports H. pylori/peptic ulcer combination therapy.
Protonix is one of several proton pump inhibitors available on the market.
Not explicitly stated in supplied label excerpts.
PPIs share the same mechanism of action in reducing stomach acid.
Not explicitly stated in supplied label excerpts.
Differences among PPIs can include pharmacokinetic profiles, potency, and potential for drug interactions.
Not explicitly stated in supplied label excerpts.
Unsupported Statements
Protonix is prescribed to treat conditions caused by too much stomach acid.
The provided excerpts support treatment of erosive esophagitis associated with GERD and pathological hypersecretory conditions including Zollinger-Ellison, but do not contain the general phrasing 'conditions caused by too much stomach acid.'
Zollinger-Ellison syndrome is a condition in which tumors cause the stomach to produce too much acid, leading to ulcers.
This disease description is not contained in the provided label excerpts.
Protonix is used for peptic ulcers in combination with antibiotics to eradicate Helicobacter pylori (H. pylori).
No provided label excerpt includes an indication for H. pylori or combination therapy for peptic ulcers.
Protonix can cause side effects including headache.
No specific adverse reaction examples (e.g., headache) are provided in the supplied adverse-reaction excerpts.
Protonix can cause side effects including diarrhea.
No specific adverse reaction examples (e.g., diarrhea) are provided in the supplied adverse-reaction excerpts.
Protonix can cause side effects including nausea.
No specific adverse reaction examples (e.g., nausea) are provided in the supplied adverse-reaction excerpts.
Protonix can cause side effects including dizziness.
No specific adverse reaction examples (e.g., dizziness) are provided in the supplied adverse-reaction excerpts.
Less common but more serious side effects of Protonix can include severe stomach pain.
No specific adverse reaction severity categories or 'severe stomach pain' are provided in the supplied adverse-reaction excerpts.
Less common but more serious side effects of Protonix can include persistent diarrhea.
No specific adverse reaction severity categories or 'persistent diarrhea' are provided in the supplied adverse-reaction excerpts.
Less common but more serious side effects of Protonix can include signs of a bone fracture.
No adverse reaction claims about bone fractures are provided in the supplied adverse-reaction excerpts.
Protonix is one of several proton pump inhibitors available on the market.
Not stated in the provided label excerpts.
Other PPIs include omeprazole (Prilosec), lansoprazole (Prevacid), esomeprazole (Nexium), and rabeprazole (AcipHex).
Not stated in the provided label excerpts.
PPIs are generally considered therapeutically interchangeable for many conditions.
Not stated in the provided label excerpts.
Clinical trials have demonstrated efficacy of pantoprazole in treating other acid-related disorders.
The provided clinical-study excerpts focus on EE associated with GERD and pathological hypersecretory conditions; 'other acid-related disorders' is not supported.
Studies have shown significant symptom relief with pantoprazole.
The provided excerpt supports symptomatic relief of erosive esophagitis and heartburn relapse reduction, but 'significant symptom relief' is a generalized statement not explicitly quoted.
Studies have shown healing rates in patients treated with pantoprazole.
While the label supports healing of erosive esophagitis, the excerpt does not explicitly support this generalized phrasing beyond the specific EE indication.
Following patent expiries, generic versions of pantoprazole are available.
Not stated in the provided label excerpts.
Generic pantoprazole contains the same active ingredient as the brand-name medication.
Not stated in the provided label excerpts.
Generic pantoprazole is approved by regulatory agencies to be safe and effective as its brand-name counterpart.
Not stated in the provided label excerpts.
Contradictions
Low
AI Statement
Protonix is used for peptic ulcers in combination with antibiotics to eradicate Helicobacter pylori (H. pylori).
Label Reference
Provided label excerpts contain Indications 1.1 (EE associated with GERD), 1.2 (maintenance of healing of EE), 1.3 (pathological hypersecretory conditions including Zollinger-Ellison). No excerpt supports H. pylori/peptic ulcer combination therapy.
Important Omissions
Contraindications: hypersensitivity to components or substituted benzimidazole.
Importance:
High
Warnings/precautions: e.g., symptomatic response does not preclude gastric malignancy; atrophic gastritis; cyanocobalamin deficiency with long-term therapy; THC urine screen false positives.
Importance:
High
Drug interaction warnings: atazanavir or nelfinavir not recommended with PPIs; increased INR/prothrombin time with warfarin; potential absorption interference with drugs dependent on gastric pH; false positive THC urine tests.
Importance:
High
Administration constraints: tablets should not be split/chewed/crushed; suspension timing (~30 minutes before meal) and apple juice/applesauce restrictions; do not administer with other liquids/foods; suspension should not be divided to create a smaller dose.
Importance:
Moderate
Dose regimens (e.g., 40 mg once daily up to 8 weeks for adults; pediatric dosing by weight; maintenance 40 mg once daily; Zollinger-Ellison 40 mg twice daily).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported adverse-effect claims and missing contraindication/interaction/warning language could mislead users about safety. The H. pylori/peptic ulcer combination claim is unsupported by the provided indications, which could promote an unlabelled use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several statements (notably H. pylori/peptic ulcer combination therapy and specific adverse-effect examples; generic interchangeability/market comparisons; generalized efficacy language) are not supported by the provided label excerpts, and label-critical items (contraindications, warnings/precautions, and drug interactions) are omitted.
Suggested Improvement
Restrict claims to the supplied label excerpts: indications (EE healing/symptom relief; maintenance; Zollinger-Ellison), formulation-specific administration instructions, and explicitly quoted warnings/interaction statements. Remove unsupported adverse-effect and H. pylori/peptic ulcer combination claims unless additional label excerpts are provided.